The positive RAD 101 Phase 2b data and planned Phase 3 initiation are significant catalysts, but the company's cash runway is critically short. Monitor for additional capital raises (ATM facility or further offerings) and progress on Phase 3 enrollment. The stock may trade on clinical momentum but faces overhang from ongoing dilution.
Price Chart
Executive Summary
Radiopharm Theranostics reported positive Phase 2b results for imaging agent RAD 101 (93% primary endpoint concordance) and plans to initiate a Phase 3 registrational trial in Q4 2026, alongside early efficacy signals from RAD 204. However, the quarterly cash flow reveals a critical cash position of $4.1M (down from $19.2M) with only 0.28 quarters of funding, partially offset by post-quarter capital raises of $12.5M institutional and a $6M Share Purchase Plan. The combination of strong clinical data and severe cash burn creates a mixed outlook for this pre-revenue biotech.
Key Facts
- RAD 101 Phase 2b met primary endpoint with 93% of evaluable patients achieving concordance with MRI; interim analysis shows 86% sensitivity (12/14 patients).
- Company plans to initiate Phase 3 registrational trial for RAD 101 in Q4 2026 with Siemens Healthineers as manufacturing partner.
- RAD 204 third cohort showed first patient with RECIST-confirmed partial response, tumor shrinkage up to -43%, progression-free after 7+ months.
- Closing cash at June 30, 2026 was $4.1 million, down from $19.2 million at prior quarter end.
- Net cash outflows from operating activities were $14.97 million for the quarter, with R&D and staff costs comprising 95%.
- Estimated quarters of funding available is 0.28 (less than one quarter).
- Post quarter-end: received FY25 Australian R&D Tax Incentive of $5.9 million, completed $12.5 million institutional offer, launched $6 million Share Purchase Plan (subscribed up to $3 million).
- Company has an At-The-Market Facility for up to US$18.9 million and expects to raise additional capital.
Financial Impact
Cash burn of A$14.97M in the quarter; cash position of A$4.1M provides less than one quarter of runway. Post-quarter capital raises of ~$12.5M (institutional) plus up to $6M (SPP) and $5.9M R&D tax credit partially address near-term funding needs.
Risk Factors
- Severe cash burn requires additional dilutive financing; only 0.28 quarters of funding at current burn rate.
- Phase 3 registrational trial for RAD 101 may not replicate Phase 2b results or may face enrollment delays.
- Early-stage pipeline (RAD 204, RAD 202, etc.) has limited clinical data and high failure risk.
- Multiple concurrent capital raises (424B5, institutional offer, SPP) signal urgency and dilute existing shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (RADX) — Batch item 1 | 0001213900-26-083624 |
| Document: ea0300004-6k_radiopharm.htm | 0001213900-26-083624 |
| Document: 0001213900-26-083624-index-headers.html | 0001213900-26-083624 |
| Document: 0001213900-26-083624-index.html | 0001213900-26-083624 |
| Document: 0001213900-26-083624.txt | 0001213900-26-083624 |
| 6-K Filing (RADX) — Batch item 6 | 0001213900-26-083624 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9600 (−3.03%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9600 (−11.11%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9600 (−24.41%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9600 (−35.14%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9600 (−40.74%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9600 (+38.93%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9600 (−41.82%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9600 (−52.24%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9600 (−51.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers